Skip to the content
[email protected]
Get in Touch
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
Menu
Home
Pipeline
Strategy
About Us
Investors
News & Events
Contact
NEWS
Highlights
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
NEWS
NEWS 2022
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
News
Highlights
News
2024
News
2023
News
2022
Archives
2016-2021
Media
Contact
Media And
Events
November 14, 2022
Appili Therapeutics ATI-1701 Biodefense Vaccine Secures ~US$14 Million of Funding from the U.S. Department of Defense in Partnership with the U.S. Air Force Academy
Read More
November 10, 2022
Appili Therapeutics Reports Financial and Operational Results for Second Quarter of Fiscal Year 2023
Read More
September 22, 2022
Appili Therapeutics Announces Results of Annual and Special Meeting of Shareholders
Read More
August 12, 2022
Appili Therapeutics Reports Financial and Operational Results for First Quarter of Fiscal Year 2023
Read More
August 2, 2022
Appili Therapeutics to Present at WorldLeish7 Conference in Cartagena, Columbia
Read More
June 29, 2022
Appili Therapeutics Reports Fiscal Year 2022 Financial and Operational Results
Read More
May 26, 2022
Appili Therapeutics Announces Closing of Public Offering of $4,500,000
Read More
May 18, 2022
Appili Therapeutics Announces Pricing of Overnight Marketed Equity Offering
Read More
May 17, 2022
Appili Therapeutics Announces Overnight Marketed Equity Offering
Read More
April 27, 2022
Appili Therapeutics to Present at the 2022 Bloom Burton & Co. Healthcare Investor Conference
Read More
April 13, 2022
Appili Therapeutics Announces New Late-Stage Clinical Program ATI-1801 to Treat Cutaneous Leishmaniasis
Read More
March 29, 2022
Appili Therapeutics Announces Non-Convertible Secured Loan of US$3.6 Million and License and Distribution Agreement with Long Zone Holdings
Read More
March 9, 2022
Appili Therapeutics to Present Live via Webcast at OTC Markets Virtual Life Sciences Investor Forum
Read More
February 28, 2022
Appili Therapeutics Announces Over US$10 Million in New Funding from US Department of Defense for Biodefense Vaccine Candidate ATI-1701
Read More
February 14, 2022
Appili Therapeutics Reports Financial and Operational Results for Third Quarter of Fiscal Year 2022
Read More
February 8, 2022
Appili Therapeutics Expands ATI-1501 Commercial Agreement with Partner Saptalis Pharmaceuticals
Read More
